YAP1 and lung carcinoma: In vitro as well as in vivo studies confirmed that YAP1/WWTR1/TEAD-dependent transcription is acutely activated after osimertinib treatment in EGFR-mutant lung cancer, and pharmacological and genetic ablation of this complex strongly inhibits persister cells.